AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03241693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blended-learning in ethics
Description: Experimental group followed clinical practices in hospital centers during 8 months.~In addition, an online specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six online related activities were created: to solve situations related to real clinical practices. Six face to face group sessions based on cooperative learning were planned in order to discuss ethical issues detected among clinical practices during 4 months. Students were divided in small groups, 4-5 participants each, and active participation techniques were used.
Study NCT03241693 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: Control group followed clinical practices in hospital centers during 8 months as usual.~In the control group, case study method was also used, thus students in control group had to create and perform a public exposition of a real clinical case about professional ethics. Cases had to be related to clinical practices in order to recognize ethical situations in the work environment. Neither online learning nor online activities were carried out.
Study NCT01047319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: One capsule containing 0.6 mg laquinimod to be administered orally once daily.
Study NCT03880474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NP+M1
Description: Trial Vaccine
Study NCT03880474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Sodium Chloride Placebo
Study NCT03150459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Description: Simvastatin 20 mg/day for 12 weeks (Group 1)
Study NCT03150459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: Simvastatin 40 mg/day for 12 weeks (Group 2)
Study NCT03150459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin 400 mg
Description: Rifaximin 400 mg/8 hours for 12 weeks (Group 1 and 2)
Study NCT03150459 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Simvastatin
Description: Placebo of Simvastatin for 12 weeks (Group 3)
Study NCT03150459 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Rifaximin
Description: Placebo of Rifaximin for 12 weeks (Group 3)
Study NCT02273167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006, 2-Day Split-Dosing
Description: The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
Study NCT02273167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006,1-Day Morning Split-Dosing
Description: The subject will self-administer the first dose of the investigational product on the morning of the colonoscopy and take mandatory additional clear fluid.~After a 1-2 hour break the subject will self-administer the second dose plus additional clear mandatory fluid.
Study NCT02273167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MOVIPREP, 2-Day Split-Dosing
Description: The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take recommended additional clear fluid. Subject will take the second dose together with recommended additional clear fluids on the morning of the colonoscopy.
Study NCT04539990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral treatment for sleep difficulties
Description: This intervention is mediated by the parents. Parents are educated regarding sleep hygiene and instructed to follow simple rules which create a reliable evening routine and reduce exposure to stimulating factors that delay sleep onset (e.g., caffeine or exercise). In addition, parents are asked to initiate a fading behavioral protocol whereby they teach their child to fall asleep independently, with less parental attention. This requires parents to limit their interaction with their child after the children are put to bed so as not to interfere with sleep onset. This includes limiting conversations and lying in bed with the child. This behavioral approach is applied gradually and is expected to reduce the time it takes children to fall asleep.
Study NCT03228030 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: Capsules
Study NCT03228030 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical capsules
Study NCT04312100 — intervention group
Intervention type: OTHER
Intervention: oxygen treatment
Description: different kinds of oxygen treatments will be given to patients according to their state of illness
Study NCT04176224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Suspension
Study NCT01989858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: peri-operative cht
Description: CHT treatment have to be chosen between the following associations:~Chemotherapy regimen containing epirubicin, cisplatin and capecitabine (EOX) E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously~or~Chemotherapy regimen containing epirubicin, cisplatin and 5-fluorouracil (ECF) E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.
Study NCT01989858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: post-operative CHT
Description: CHT treatment have to be chosen between the following associations:~EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously~or ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5fluorouracil (5FU) 200 mg/m² daily by continuous infusion via central line.
Study NCT01989858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: peri-operative cht + post-operative cht-rtx
Description: CHT treatment have to be chosen between the following associations:~* EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously or~* ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.~The prescribed RTX dose to clinical target volume should be 45 gray (Gy) delivered in daily fraction of 1.8 Gy, five times per week for six weeks. RTX will be administered concurrently with CHT. The choice of the associated CHT should be between the following schedules:~* 5FU 225 mg/m² given as a continuous iv infusion or~* capecitabine 825 mg/m² bid given as a continuous oral administration during the entire course of RTX.
Study NCT04152304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sinex program (neuromuscular training program)
Description: The SINEX program is a three months neuromuscular training program aiming to increase neuromuscular stability of the shoulder
Study NCT01736800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Patients will receive Topotecan intravenous treatment days 2-6 of each 28-day cycle at The Mehthodist Hospital Outpatient Infusion Center.
Study NCT01989858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: post-operative cht + post-operative cht-rtx
Description: CHT treatment have to be chosen between the following associations:~* EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously or~* ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.~The prescribed RTX dose to clinical target volume should be 45 gray (Gy) delivered in daily fraction of 1.8 Gy, five times per week for six weeks. RTX will be administered concurrently with CHT. The choice of the associated CHT should be between the following schedules:~* 5FU 225 mg/m² given as a continuous iv infusion or~* capecitabine 825 mg/m² bid given as a continuous oral administration during the entire course of RTX.
Study NCT02160626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A-101 Vehicle
Description: Placebo control
Study NCT02160626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-101 (40) Topical Solution
Description: A-101 (40) Topical Solution - high dose
Study NCT02160626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-101 (32.5) Topical Solution
Description: A-101 (32.5) Topical Solution - low dose
Study NCT01326871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 1 of each course (if given)
Study NCT01326871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II); on day 1 and 8 of each course
Study NCT01326871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 3, 5, 8, and 12 of each course
Study NCT01736800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is taken on an empty stomach at night and should not be chewed. Patients receive Temozolomide on days 1-5 of a 28-day schedule.
Study NCT00171808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study NCT00560560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CP-751, 871
Description: Human IgG2 Monoclonal Antibody. 20mg/kg or 30 mg/kg every 3 weeks for 17 cycles, until progression or unacceptable toxicity develops.
Study NCT02869516 — intervention group
Intervention type: OTHER
Intervention: Clinical data collection
Study NCT01629732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Film coated tablet, Oral, 60 mg, Once daily, 12 or 24 weeks
Study NCT01629732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Film coated tablet, Oral, 60 mg, Once daily, 24 weeks
Study NCT00805259 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial incentives
Description: Financial incentives based on use of software designed to promote cognitive function
Study NCT01629732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986094
Description: Capsule, Oral, 100 mg, Once daily, 12 or 24 weeks
Study NCT01629732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986094
Description: Capsule, Oral, 200 mg, Once daily, 12 or 24 weeks
Study NCT01629732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986094
Description: Capsule, Oral, 200 mg, Once daily, 24 Weeks
Study NCT01629732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Film coated tablet, Oral, 1000 mg or 1200 mg based on weight, Twice daily, 12 or 24 weeks
Study NCT01629732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BMS-986094
Description: Capsule, Oral, 0 mg, Once daily, 12 or 24 weeks
Study NCT00037830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM1 ganglioside
Description: 100 mg twice per day by subcutaneous injection
Study NCT00037830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice per day subcutaneous injection, equal volume as active drug
Study NCT03651622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypocaloric, low carbohydrate diet
Description: Participants will be advised on use of a hypocaloric, low carbohydrate diet using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
Study NCT03651622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypocaloric, moderate low fat diet
Description: Participants will be advised on use of a hypocaloric, moderate low fat diet using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
Study NCT03651622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet, no caloric restriction
Description: Participants will be advised on use of a healthy Mediterranean-based eating plan using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
Study NCT01269723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Broccoli sprout homogenate
Description: Subjects will drink the broccoli shake homogenate
Study NCT01269723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alfalfa sprout homogenate
Description: Subjects will drink the alfalfa sprout homogenate.
Study NCT01517295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone
Description: Dose: Standard prescribed dose Frequency: Once Duration: Once
Study NCT04559984 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: JUVÉDERM VOLUX®
Description: JUVÉDERM VOLUX® injectable gel
Study NCT04559984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM VOLUX®
Description: JUVÉDERM VOLUX® injectable gel
Study NCT03353220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belviq
Description: Belviq is an oral drug
Study NCT00741559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetoencephalography
Description: MEG studies are performed using a whole-head Omega 151-channel gradiometer system.
Study NCT00741559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)
Description: An interictal FDG(fluoro-D-glucose)-PET will be obtained in a single 10 minute scanning session. PET scans will be obtained using a 3D acquisition technique, which will allow the use of a lower dose of radiotracer.
Study NCT00741559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: MR will be performed on a 1.5T or 3T system, using a combination of different sequences including sagittal T1, coronal and axial T2, FLAIR and proton density and axial 3D T1 weighted images.
Study NCT01786759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ClinOleic
Description: the lipid of all-in-one, 0.5-3.5g/kg.d
Study NCT01786759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ClinOleic
Description: the lipid of all-in-one, 0.5-3.5g/kg.d
Study NCT01786759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid
Description: the lipid of all-in-one, 0.5-3.5g/kg.d
Study NCT01786759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid
Description: the lipid of all-in-one, 0.5-3.5g/kg.d
Study NCT01432184 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: strategies to reverse decrease in rSO2
Description: an alarm threshold at a value of 90% of the resting baseline cerebral saturation value (baseline - 10%) will be established. To minimize the probability of patients reaching significant decreases rSO2 values, interventions to improve cerebral oxygenation will be initiated according to the strategies described in the algorithm. The success and failure of these interventions will be noted. As in the Control group, the screen will remain blinded in the ICU and the intensivist will not see the values.
Study NCT02840344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples MBSR
Description: Both members of the couple will be asked to participate in the weekly video sessions and activities.
Study NCT02840344 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual MBSR
Description: Only the young breast cancer survivor will participate in the weekly video sessions and activities.
Study NCT03472248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Eight weeks of smartphone delivered Acceptance and Commitment Therapy for the adolescent and eight weeks of internet delivered parental support to one or two parents of the adolescent.
Study NCT00006011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT03353220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo is made to mimic Belviq, but does not contain any active drug
Study NCT03186755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid 0.05% & Ectoine 2.0%
Description: Treatment of 1 drop three times a day in both eyes for 8 weeks
Study NCT03186755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine hydrochloride ophthalmic solution 0.1%
Description: Treatment of 1 drop two times a day in both eyes for 8 weeks
Study NCT00666237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tube shunt surgery
Description: The procedure involves implantation of a Baerveldt consisting of a tube that is connected to an end plate. The tube is inserted into the anterior chamber and shunts aqueous humor to the end plate located in the equatorial region of the eye. The aqueous humor is then absorbed by the tissues around the eye.
Study NCT00666237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Description: The procedure involves removal of a small portion of trabecular meshwork and adjacent tissue under a partial thickness scleral flap. Aqueous humor drains into the subconjunctival space producing a filtering bleb. The aqueous humor then diffuse out of the bleb.
Study NCT00666237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: A fluid retaining sponge soaked in 0.4 mg/ml Mitomycin C will be applied in the region of Trabeculectomy site for about 2 minutes
Study NCT01548599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-sectoral agricultural intervention
Description: Participants in the intervention arm will receive a micro-finance loan and training on financial management and marketing skills. With the loan, each participant will receive vouchers to purchase the following items: the Money Maker hip pump, 50 feet of hosing, fertilizer, and government certified seeds. Participants in the intervention group will also receive training on the use of the Money Maker hip pump, a portable, low-cost, human-powered water pump developed by KickStart. Participants in the intervention group will also receive training from Kickstart on the use of the pump as well as complementary training in best horticultural practices.
Study NCT02873689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole delayed-release capsule
Study NCT02873689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dexlansoprazole placebo-matching capsules
Study NCT04361656 — intervention group
Intervention type: DRUG
Intervention: PEG-ELS current standard of care
Description: Standard of care for inpatient colonoscopy
Study NCT04361656 — intervention group
Intervention type: DRUG
Intervention: PEG-ELS current standard of care plus Lubiprostone 24 microgram Oral Cap (x2)
Description: The dose of Lubiprostone will be 24 mcg capsule orally (roughly every 12 hours) for total of 2 doses, with the last dose being at least 4 hours prior to the scheduled colonoscopy if it is BEFORE 11 a.m., and Lubiprostone 24 mcg capsule orally 2 hours before each dose of the PEG-ELS if colonoscopy is scheduled AT or AFTER 11 a.m..
Study NCT00981617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS33 (RDC-0313) (1 mg)
Description: 1 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
Study NCT00981617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS33 (RDC-0313) (2.5 mg)
Description: 2.5 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
Study NCT00006011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00006011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT00006011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC
Study NCT00006011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT00831753 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP IPV HB PRP~T vaccine
Description: 0.5 mL, Intramuscular
Study NCT00831753 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-HB-IPV and Haemophilus influenzae type b
Description: 0.5 mL, Intramuscular